OncoMatch/Clinical Trials/NCT07450859
A Study of BT5528 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
Is NCT07450859 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies BT5528 for pancreatic ductal adenocarcinoma (pdac).
Treatment: BT5528 — This is a Phase 2 study for BT5528 in adults with a specific type of pancreatic cancer called metastatic pancreatic ductal adenocarcinoma (PDAC) that has spread and worsened after one previous treatment. The drug, BT5528, is designed to find a specific protein called EphA2. The main aims of the study are to see how well the drug works against the tumor (efficacy), what side effects it may have (safety), and how the body processes it (pharmacokinetics). All participants in this study will receive BT5528, and both they and their doctors will know what is being administered (single-arm, open-label). The trial will take place at several different medical centers.
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Biomarker criteria
Required: EPHA2 expression (testing required)
sufficient tumor tissue (fresh or archived) available for analysis of EphA2 tumor expression and other biomarkers
Excluded: MSI1 microsatellite instability-high (MSI-H)
Known microsatellite instability-high (MSI-H) status and are eligible for immune checkpoint inhibitor therapy
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic therapy
Participants must have failed only 1 prior line of therapy with evidence of radiographic progression. Neoadjuvant or adjuvant systemic therapy may count as the first line if the participant progressed less than 6 months from the end of systemic therapy.
Cannot have received: taxane (paclitaxel)
Prior treatment with taxane therapy (e.g., paclitaxel) for pancreatic cancer
Cannot have received: antibody-drug conjugate
prior treatment with any MMAE-containing agent
Lab requirements
Blood counts
adequate organ function (hematologic, renal, and hepatic)
Kidney function
adequate organ function (hematologic, renal, and hepatic)
Liver function
adequate organ function (hematologic, renal, and hepatic)
Adequate organ function (hematologic, renal, and hepatic)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Thomas Jefferson University, Sidney Kimmel Comprensive Cancer Center, Clinical Trials Office · Philadelphia, Pennsylvania
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify